<DOC>
	<DOCNO>NCT02594293</DOCNO>
	<brief_summary>This study evaluate whether Peg-IFN alfa-2a reduce recurrence rate hepatitis B 96 week nucleoside analogue ( NUC ) withdrawal . The HBV HBeAg-Negative patient receive NUC anti-virus treatment 2.5 year reach stop rule 《Chinese chronic hepatitis B prevention treatment guidelines》 ( 2010 ) randomly assign three group : One group discontinue NUC treatment follow 96 week , One discontinue NUC treatment , receive Peg-IFN alfa-2a 180 μg week 24 week follow 72 week , The discontinue NUC treatment , receive Peg-IFN alfa-2a 180 μg week 48 week follow 48 week .</brief_summary>
	<brief_title>Pegylated Interferon ( Peg-IFN ) Reducing Relapse Rate Patients After Discontinuation NUC Therapy</brief_title>
	<detailed_description>NUC potent inhibitor hepatitis B viral ( HBV ) replication , long-term therapy may require . Therefore , NUC resistance important clinical risk result long-term therapy chronic hepatitis B ( CHB ) management . Discontinuation NUC feasible strategy reduce resistance . However , high rate relapse cessation NUC treatment CHB patient remain big problem . NUC treatment safely stop drug need solve . Peg-IFN clear HBV direct anti-viral immune regulation mechanism include enhance natural killer cell response , increase cluster differentiation 8 ( CD8 + ) T lymphocytes mechanism restore enhance immune response patient CHB . Response PEG-IFN frequently sustain finite treatment course due immune modulate capacity .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . HBeAgNegative Chronic Hepatitis B Patients：HBsAgPositive , HBsAbNegative , HBeAgNegative , HBeAbPositive screen period NA treatment 2 . NUC monotherapy ( include adefovir entecavir ) 2.5 year , reach stop rule 《Chinese chronic hepatitis B prevention treatment guidelines》 ( 2010 ) : patient achieve undetectable HBV DNA ( &lt; 300 copies/mL ) normal alanine aminotransferase ( ALT ) consolidation therapy reach 1.5 year , total course treatment reach 2.5 year stop NUC therapy 3 . Willing stop drug , sign write informed consent 1 . HBsAb positive screening period 2 . Compensated Decompensated liver cirrhosis : history cirrhosis NUC treatment ChildPugh score ≥ 5 Complications liver cirrhosis ascites , hepatic encephalopathy , esophageal gastric varix bleed 3 . Hypersensitivity interferon ( IFN ) active substance , ineligible IFN 4 . A history immunoregulation drug therapy within one year entry include IFN . 5 . Coinfection HAV、HCV、HDV、HEV 、HIV Other chronic liver diseases Alcoholic Liver Disease , Inherited Metabolic Liver Disease , Drug induce Liver Disease nonalcoholic fatty liver 6 . Autoimmune disease include Autoimmune hepatitis Psoriasis . 7 . Hepatocellular carcinoma ( HCC ) alpha feto protein ( AFP ) level 100 ng/ml Hepatic malignant potential Imaging examination AFP level 100 ng/ml 3 month 8 . A neutrophil count less 1500 per cubic millimeter platelet count le 90,000 per cubic millimeter 9 . A serum creatinine level 1.5 time upper limit normal range 10 . With malignant tumor ( exclude cure one ) 11 . Severe organ dysfunction 12 . With severe psychiatric condition nervous disease epilepsy , depression , mania , epilepsy , schizophrenia 13 . Uncontrolled diabetes , hypertension thyroid disease 14 . Pregnant woman lactate woman patient pregnancy plan willing use contraception study period 15 . Participate clinical study time 16 . Patients unsuitable research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>